Vulvovaginal candidiasis-an overview of current trends and the latest treatment strategies.
Bhosale VB, Koparde AA, Thorat VM.
Microb Pathog. 2025 Mar;200:107359. doi: 10.1016/j.micpath.2025.107359. Epub 2025 Feb 5.
PMID:39921042
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
Wang X, Chen L, Ruan H, Xiong Z, Wang W, Qiu J, Song W, Zhang C, Xue F, Qin T, Zhang B, An R, Luo X, Wang W, Zhang S, Cai Y, Kang J, Deng H, Fan S, Cui M, Wang S, Luo X, Su Z, Shu J, Wang Q, Wang F, Bai J, Liao Q.
Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0077823. doi: 10.1128/aac.00778-23. Epub 2023 Dec 14.
BMJ. 2020 Jun 8;369:m1995. doi: 10.1136/bmj.m1995.
PMID:32513647
Recurrent vulvovaginal candidiasis.
Ringdahl EN.
Mo Med. 2006 Mar-Apr;103(2):165-8.
PMID:16703718
Biofilms and vulvovaginal candidiasis.
Rodríguez-Cerdeira C, Gregorio MC, Molares-Vila A, López-Barcenas A, Fabbrocini G, Bardhi B, Sinani A, Sánchez-Blanco E, Arenas-Guzmán R, Hernandez-Castro R.
Colloids Surf B Biointerfaces. 2019 Feb 1;174:110-125. doi: 10.1016/j.colsurfb.2018.11.011. Epub 2018 Nov 7.
PMID:30447520
Advanced Solid Formulations For Vulvovaginal Candidiasis.
Conte J, Parize AL, Caon T.
Pharm Res. 2023 Feb;40(2):593-610. doi: 10.1007/s11095-022-03441-5. Epub 2022 Nov 30.